HSD17B1 (C-term)

GWB-793727

A synthetic peptide corresponding to residues on the C-terminus of human HSD17B1 was used as an immunogen.

WB: 1:100 000IHC: 1: 100 250ICC: 1:100 250FC: 1:15IP: 1:100. The principal human estrogen 17 beta-estradiol is a potent stimulator of certain endocrine-dependent forms of breast cancer. Because human estrogenic 17 beta-hydroxysteroid dehydrogenase (HSD17B1) catalyzes the last step in the biosynthesis of 17 beta-estradiol from the less potent estrogen estrone it is an attractive target for the design of inhibitors of estrogen production and tumor growth (1). It is concluded that the steroid-binding site of human placental HSD17B1 contains a histidine residue which proximates the upper A-ring region of the steroid as it undergoes the reversible binding step (2). Human estrogenic HSD17B1 is an NADP(H)-preferring enzyme. It possesses 11- and 4-fold higher specificity toward NADP(H) over NAD(H) for oxidation and reduction respectively as demonstrated by kinetic studies (3). Defects in the conversion of androstenedione to testosterone in the fetal testes by the enzyme HSD17B1 give rise to genetic males with female external genitalia (4) 1. Takagi K Miki Y Nagasaki S et al Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment Endocr Relat Cancer 17 (2010) 415-430[Application: IHC]1. Murdock GL et al. J Biol Chem 258(19):11460-4 1983. 2. Ghosh D et al. Structure 3(5):503-13 1995. 3. Huang YW et al. Mol Endocrinol 15(11):2010-20 20014. Geissler WM et al. Nat Genet 7(1):34-9 1994. 5. Manufactured under U. S. Patents No. 5 675 063 and 7 429 487